ONCTERNAL THERAPEUTICS INC (ONCT)

US68236P2065 - Common Stock

8.22  +0.02 (+0.24%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ONCTERNAL THERAPEUTICS INC

NASDAQ:ONCT (3/28/2024, 10:58:15 AM)

8.22

+0.02 (+0.24%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap24.33M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ONCT Daily chart

Company Profile

Oncternal Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 30 full-time employees. The company went IPO on 2004-02-03. Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

Company Info

ONCTERNAL THERAPEUTICS INC

12230 El Camino Real, Suite 230

San Diego CALIFORNIA 92130

P: 18584341113

CEO: James B. Breitmeyer

Employees: 30

Website: https://www.oncternal.com/

ONCT News

News Image13 days ago - Oncternal TherapeuticsOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

News Image21 days ago - InvestorPlaceONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

ONCT stock results show that Oncternal Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

News Image21 days ago - BusinessInsiderONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncternal Therapeutics (NASDAQ:ONCT) just reported results for the fourth quart...

News Image21 days ago - Oncternal TherapeuticsOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with...

News Image2 months ago - Oncternal TherapeuticsOncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

News Image2 months ago - Oncternal TherapeuticsOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT Twits

Here you can normally see the latest stock twits on ONCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example